Prescient Metabiomics (a subsidiary of Prescient Medicine Holdings) and CoreBiome (a wholly-owned subsidiary of OraSure Technologies), have announced a collaboration to develop a new test called LifeKit Prevent, which may represent a microbiome-driven paradigm shift in colon cancer screening.
"CoreBiome's DNA sequencing platform and innovative bioinformatics methods for data analysis will be critical for development of the LifeKit® Prevent test," said Prescient Medicine CEO, Dr Keri Donaldson. "Prescient Metabiomics will leverage CoreBiome's discovery platform to accelerate development and validation through the FDA's Breakthrough Devices Program."
There is currently a lack of non-invasive screening tests that can accurately detect precancerous polyps as effectively as a colonoscopy. The current standard of care for colon cancer prevention is in-clinic screening via colonoscopy, but approximately one in three patients are not up-to-date with their necessary colon cancer screenings. Research indicates that early detection of precancerous adenomas and carcinomas could lead to significantly better patient outcomes.
To help address this issue, Prescient Metabiomics is developing a unique assay for predicting precancerous adenomas and carcinomas that uses microbial biomarkers as a diagnostic platform. Prescient Metabiomics has teamed up with CoreBiome to utilise shotgun metagenomics DNA sequencing, machine learning and AI-driven microbiome analytics to accelerate their development pipeline.
"CoreBiome is committed to producing ultra-high-quality data at very large scales and helping customers perform data mining for clinical biomarkers,” said CoreBiome CEO, Dan Knights. We are excited to help Prescient Metabiomics move into the clinic faster by combining our precisely controlled data generation with Prescient Metabiomics' customized analysis algorithms and machine learning.”